Identification of a Novel Complex BRAF Mutation Associated With Major Clinical Response to Vemurafenib in a Patient With Metastatic Melanoma

• Autores: Benoit Busser, Marie Therese Leccia, Guillaume Gras-Combe, Ivan Bricault, Isabelle Templier
• Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 149, Nº. 12, 2013, págs. 1403-1406
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Importance There is an increasing interest in BRAF V600 mutations in melanomas and their associated sensitivity to vemurafenib, a BRAF inhibitor. However, physicians cannot find information in the literature about vemurafenib response for rare and/or atypical BRAF mutations.

    Observations We describe the identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma. Using a pyrosequencing method, we determined that the tumor positive for mutated BRAF, uncovering a novel c.1799_1803delinsAT; p.V600-K601>D variant. We uncovered this atypical BRAF mutation with 2 different sequencing methods, both in the primary lesion and in 1 metastasis. The patient was immediately treated with vemurafenib as monotherapy and achieved a prolonged (5.5-month) positive response.

    Conclusions and Relevance We analyzed the consequences of the BRAF V600-K601>D mutation in terms of amino acids. We referred to the published data and databases to screen chemical properties of well-known BRAF V600 mutations and other complex BRAF mutations to find common features of activated BRAF mutations. Importantly, we highlighted that both the site of the mutation and the involved amino acids are important to predict vemurafenib response. Our conclusion is that complex BRAF mutation surrounding codon 600 could also be sensitive to BRAF inhibitors.

    .